Understanding and Optimizing Bone Health in Breast Cancer

Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980

(2017) C. L. Shapiro et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study

(2017) J. Lester et al.   JOURNAL OF CLINICAL ONCOLOGY

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

(2010) R E Coleman et al.   BRITISH JOURNAL OF CANCER

Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women's Health Initiative (WHI).:

(2010) R. Chlebowski et al.   CANCER RESEARCH

The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up.

(2010) A. Brufsky et al.   CANCER RESEARCH

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

(2010) HT Mouridsen et al.   CANCER RESEARCH

A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases.

(2010) A. Stopeck et al.   CANCER RESEARCH

Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer.

(2010) G. Rennert et al.   CANCER RESEARCH

Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST.:

(2010) R. Coleman et al.   CANCER RESEARCH

Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women?

(2010) Michael Gnant   JOURNAL OF CLINICAL ONCOLOGY

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

(2010) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

(2010) Rebecca Aft et al.   LANCET ONCOLOGY

Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study

(2009) Georgiana K. Ellis et al.   BREAST CANCER RESEARCH AND TREATMENT

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

(2008) Bent Kristensen et al.   ACTA ONCOLOGICA

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow--a long-term follow-up

(2008) I. J. Diel et al.   ANNALS OF ONCOLOGY

Exploring the anti-tumour activity of bisphosphonates in early breast cancer

(2008) M.C. Winter et al.   CANCER TREATMENT REVIEWS

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

(2008) A. Lipton et al.   CLINICAL CANCER RESEARCH

Molecular mechanisms and treatment of bone metastasis

(2008) Gregory A. Clines et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer

(2008) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer

(2008) Fred Saad et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY

Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives

(2008) A. M. Brufsky   ONCOLOGIST

Metastasis: a therapeutic target for cancer

(2008) Patricia S Steeg et al.   Nature clinical practice. Oncology